Enliven Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$119.7M | -$104.6M | -$83.5M | -$38.8M | -$51.4M |
| Operating expenses | $119.7M | $104.6M | $83.5M | $38.8M | $51.4M |
| Cash from operations | -$70.3M | -$73.2M | -$61.3M | -$32.1M | -$46.8M |
| Capital expenditure | $158,000 | $44,000 | $149,000 | $612,000 | $12,000 |
| Free cash flow | -$70.5M | -$73.2M | -$61.4M | -$32.7M | -$46.8M |
| Impairments | $0 | $0 | — | — | — |
| Total assets | $476.2M | $325.8M | $271.9M | $83.3M | $93.6M |
| Total liabilities | $16.6M | $15.9M | $26.0M | $10.4M | $7.6M |
Shares outstanding 60.9M · Free float 62.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.